Midatech Pharma to Acquire DARA BioSciences

Merck & Co. (Merck Sharp & Dohme) Acquires Cidara Therapeutics

January 8, 2026

Biotechnology

Merck Sharp & Dohme LLC (Merck & Co., Inc.) completed its cash tender offer and follow-on merger to acquire Cidara Therapeutics, Inc. for $221.50 per share, valuing the deal at about $9.2 billion. The acquisition adds Cidara’s late-stage, long-acting, strain-agnostic influenza antiviral candidate CD388 to Merck’s respiratory pipeline.

Valo Health Acquires TARA Biosystems

April 5, 2022

Biotechnology

Valo Health has acquired TARA Biosystems, a New York City–based company specializing in human 3D tissue engineering and cardiac disease modeling, to create an integrated cardiovascular drug discovery and development platform. The deal combines TARA's in vitro cardiac models with Valo's Opal computational platform to expand Valo's capabilities in cardiovascular drug discovery and accelerate development of new therapies.

Medix Biochemica Group Acquires Bioresource Technology (BRT)

June 21, 2022

Biotechnology

Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.

Bristol Myers Squibb to Acquire Mirati Therapeutics in $4.8B Cash-and-CVR Deal

October 13, 2023

Pharmaceuticals

Bristol Myers Squibb has entered into a definitive merger agreement to acquire Mirati Therapeutics for $58 per share in cash, valuing the transaction at $4.8 billion in equity value. The deal also includes a non-tradeable contingent value right (CVR) that could provide up to an additional $1 billion of value tied to regulatory acceptance of an NDA for Mirati’s MRTX1719.

Thomas H. Lee Partners and Frazier Healthcare Partners Acquire Adare Pharmaceuticals

September 22, 2020

Pharmaceuticals

Thomas H. Lee Partners and Frazier Healthcare Partners have acquired Adare Pharmaceuticals (to be rebranded Adare Pharma Solutions) from TPG Capital. The deal includes Adare’s CDMO, pharmaceutical technology and microbiome businesses while TPG retained rights to an EoE product spun into a separate entity; terms were not disclosed.

Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

December 1, 2020

Pharmaceuticals

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.